{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:49:00Z","timestamp":1793040540056,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD24\/0004\/0010"],"award-info":[{"award-number":["RD24\/0004\/0010"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RICORS2040 RD21\/0005\/0020"],"award-info":[{"award-number":["RICORS2040 RD21\/0005\/0020"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD016\/0009"],"award-info":[{"award-number":["RD016\/0009"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010769","name":"Axencia Galega de Innovaci\u00f3n","doi-asserted-by":"publisher","award":["IN607B2023\/07"],"award-info":[{"award-number":["IN607B2023\/07"]}],"id":[{"id":"10.13039\/501100010769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010769","name":"Axencia Galega de Innovaci\u00f3n","doi-asserted-by":"publisher","award":["IN607B 2016\/020"],"award-info":[{"award-number":["IN607B 2016\/020"]}],"id":[{"id":"10.13039\/501100010769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bcp.2025.116858","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T20:14:45Z","timestamp":1741724085000},"page":"116858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Therapeutic opportunities in polycystic kidney and liver disease through extracellular matrix dynamics"],"prefix":"10.1016","volume":"236","author":[{"given":"Adrian","family":"Cordido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Nu\u00f1ez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaya","family":"Lamas-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Vizoso-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candido","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus M","family":"Banales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Garc\u00eda-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.116858_b0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMra022161","article-title":"Polycystic Kidney Disease","author":"Wilson","year":"2004","journal-title":"N Engl J Med. Published Online"},{"issue":"5","key":"10.1016\/j.bcp.2025.116858_b0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fped.2017.00279","article-title":"The Genetic and Cellular Basis of Autosomal Dominant Polycystic Kidney Disease\u2014A Primer for Clinicians","volume":"5","author":"Cordido","year":"2017","journal-title":"Front Pediatr."},{"issue":"12","key":"10.1016\/j.bcp.2025.116858_b0015","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.3390\/ijms22126523","article-title":"Molecular Pathophysiology of Autosomal Recessive Polycystic Kidney Disease","volume":"22","author":"Cordido","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.116858_b0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-013-2706-2","article-title":"ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies","volume":"30","author":"Bergmann","year":"2015","journal-title":"Pediatr. Nephrol.."},{"issue":"1","key":"10.1016\/j.bcp.2025.116858_b0025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","article-title":"Polycystic kidney disease","volume":"4","author":"Bergmann","year":"2018","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"1","key":"10.1016\/j.bcp.2025.116858_b0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-9-69","article-title":"Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management","volume":"9","author":"Cnossen","year":"2014","journal-title":"Orphanet J Rare Dis."},{"issue":"01","key":"10.1016\/j.bcp.2025.116858_b0035","doi-asserted-by":"crossref","first-page":"045","DOI":"10.1055\/s-0036-1597817","article-title":"New Advances in Polycystic Liver Diseases","volume":"37","author":"Santos-Laso","year":"2017","journal-title":"Semin Liver Dis."},{"issue":"4","key":"10.1016\/j.bcp.2025.116858_b0040","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jhep.2017.11.024","article-title":"Clinical management of polycystic liver disease","volume":"68","author":"van Aerts","year":"2018","journal-title":"J Hepatol."},{"issue":"3","key":"10.1016\/j.bcp.2025.116858_b0045","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1152\/physiol.00032.2014","article-title":"Molecular pathways and therapies in autosomal-dominant polycystic kidney disease","volume":"30","author":"Saigusa","year":"2015","journal-title":"Physiology."},{"issue":"3","key":"10.1016\/j.bcp.2025.116858_b0050","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","article-title":"Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: A position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol. Dial. Transplant.."},{"issue":"6","key":"10.1016\/j.bcp.2025.116858_b0055","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/phar.1421","article-title":"Review of tolvaptan for Autosomal dominant polycystic kidney disease","volume":"34","author":"Baur","year":"2014","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.bcp.2025.116858_b0060","doi-asserted-by":"crossref","unstructured":"Chebib FT Torres VE Assessing risk of rapid progression in autosomal dominant polycystic kidney disease and special considerations for disease-modifying therapy Am. J. Kidney Dis. 78 2 2021 282 292 10.1053\/j.ajkd.2020.12.020.","DOI":"10.1053\/j.ajkd.2020.12.020"},{"issue":"3","key":"10.1016\/j.bcp.2025.116858_b0065","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: A new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Le","year":"2016","journal-title":"J Am Soc Nephrol."},{"issue":"10","key":"10.1016\/j.bcp.2025.116858_b0070","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.bbadis.2011.06.012","article-title":"Fibrosis and progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD)","volume":"1812","author":"Norman","year":"2011","journal-title":"BBA (BBA) - Molecular Basis of Disease."},{"issue":"12","key":"10.1016\/j.bcp.2025.116858_b0075","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrgastro.2014.155","article-title":"Polycystic liver diseases: advanced insights into the molecular mechanisms","volume":"11","author":"Perugorria","year":"2014","journal-title":"Nat. Rev. Gastroenterol Hepatol."},{"key":"10.1016\/j.bcp.2025.116858_b0080","volume":"Vol 148","author":"Parrish","year":"2017","journal-title":"Matrix Metalloproteinases in Kidney Disease: Role in Pathogenesis and Potential as a Therapeutic Target"},{"key":"10.1016\/j.bcp.2025.116858_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109648","article-title":"Molecular pathways involved in injury-repair and ADPKD progression","volume":"72","author":"Formica","year":"2020","journal-title":"Cell. Signal.."},{"issue":"4","key":"10.1016\/j.bcp.2025.116858_b0090","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/03008209609028882","article-title":"Matrix metalloproteinase activity in human intrahepatic biliary epithelial cell lines from patients with autosomal dominant polycystic kidney disease","volume":"33","author":"Murray","year":"1996","journal-title":"Connect. Tissue Res.."},{"issue":"3","key":"10.1016\/j.bcp.2025.116858_b0095","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.2353\/ajpath.2010.090658","article-title":"Hepato-renal pathology in Pkd2ws25\/- mice, an animal model of autosomal dominant polycystic kidney disease","volume":"176","author":"Stroope","year":"2010","journal-title":"Am. J. Pathol.."},{"issue":"7","key":"10.1016\/j.bcp.2025.116858_b0100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/liv.12337","article-title":"Matrix metalloproteinase-10 expression is induced during hepatic injury and plays a fundamental role in liver tissue repair","volume":"34","author":"Garcia-Irigoyen","year":"2014","journal-title":"Liver Int.."},{"issue":"10","key":"10.1016\/j.bcp.2025.116858_b0105","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1136\/gutjnl-2013-305281","article-title":"Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases","volume":"63","author":"Urribarri","year":"2014","journal-title":"Gut."},{"issue":"713","key":"10.1016\/j.bcp.2025.116858_b0110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq5930","article-title":"A TGF\u03b2-ECM-integrin signaling axis drives structural reconfiguration of the bile duct to promote polycystic liver disease","volume":"15","author":"Waddell","year":"2023","journal-title":"Sci Transl Med."},{"issue":"5","key":"10.1016\/j.bcp.2025.116858_b0115","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ceb.2012.06.002","article-title":"The extracellular matrix and ciliary signaling","volume":"24","author":"Seeger-Nukpezah","year":"2012","journal-title":"Curr Opin Cell Biol."},{"issue":"12","key":"10.1016\/j.bcp.2025.116858_b0120","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nrneph.2016.157","article-title":"The contribution of branching morphogenesis to kidney development and disease","volume":"12","author":"Short","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.bcp.2025.116858_b0125","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.2000.279.5.F891","article-title":"Matrix metalloproteinases and their inhibitors regulate in vitro ureteric bud branching morphogenesis","author":"Pohl","year":"2000","journal-title":"Am J Physiol Renal Physiol."},{"issue":"3","key":"10.1016\/j.bcp.2025.116858_b0130","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/1479-7364-4-3-194","article-title":"Update of human and mouse matrix metalloproteinase families","volume":"4","author":"Jackson","year":"2010","journal-title":"Hum. Genomics."},{"issue":"S1","key":"10.1016\/j.bcp.2025.116858_b0135","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/14756366.2016.1161620","article-title":"Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs","volume":"31","author":"Jab\u0142o\u0144ska-Trypu\u0107","year":"2016","journal-title":"J Enzyme Inhib Med Chem."},{"key":"10.1016\/j.bcp.2025.116858_b0140","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/ajprenal.00421.2006","article-title":"Role of matrix metalloproteinases in renal pathophysiologies","volume":"292","author":"Catania","year":"2007","journal-title":"Am J Physiol Renal Physiol."},{"issue":"1","key":"10.1016\/j.bcp.2025.116858_b0145","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ki.1996.10","article-title":"Tubular gelatinase A (MMP-2) and its tissue inhibitors in polycystic kidney disease in the Han:SPRD rat","volume":"49","author":"Schaefer","year":"1996","journal-title":"Kidney Int.."},{"issue":"3","key":"10.1016\/j.bcp.2025.116858_b0150","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/ki.1996.383","article-title":"Matrix metalloproteinases and TIMPS in cultured C57BL\/6J-cpk kidney tubules","volume":"50","author":"Rankin","year":"1996","journal-title":"Kidney Int.."},{"key":"10.1016\/j.bcp.2025.116858_b0155","article-title":"Matrix Metalloproteinase-2 in a Murine Model of Infantile-Type Polycystic Kidney","author":"Rankin","year":"1999","journal-title":"Disease.;"},{"issue":"1","key":"10.1016\/j.bcp.2025.116858_b0160","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000013552","article-title":"Elevation of Serum Levels of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-1 and Type IV Collagen, and Plasma Levels of Metalloproteinase-9 in Polycystic Kidney Disease","volume":"20","author":"Nakamura","year":"2000","journal-title":"Am J Nephrol."},{"issue":"16","key":"10.1016\/j.bcp.2025.116858_b0165","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/hmg\/ddm141","article-title":"Genetic interaction studies link autosomal dominant and recessive polycystic kidney disease in a common pathway","volume":"16","author":"Garcia-Gonzalez","year":"2007","journal-title":"Hum Mol Genet."},{"issue":"12","key":"10.1016\/j.bcp.2025.116858_b0170","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1097\/01.ASN.0000144204.01352.86","article-title":"A Functional Floxed Allele of Pkd1 that Can Be Conditionally Inactivated In Vivo","volume":"15","author":"Piontek","year":"2004","journal-title":"J Am Soc Nephrol."},{"issue":"12","key":"10.1016\/j.bcp.2025.116858_b0175","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/nm1675","article-title":"A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1","volume":"13","author":"Piontek","year":"2007","journal-title":"Nat. Med.."},{"key":"10.1016\/j.bcp.2025.116858_b0180","doi-asserted-by":"crossref","unstructured":"Cordido A, Vizoso-Gonzalez M, Nu\u00f1ez-Gonzalez L, et al. Quantitative Proteomic Study Unmasks Fibrinogen Pathway in Polycystic Liver Disease. Biomedicines 2022, Vol 10, Page 290. 2022;10(2):290. doi:10.3390\/BIOMEDICINES10020290.","DOI":"10.3390\/biomedicines10020290"},{"key":"10.1016\/j.bcp.2025.116858_b0185","doi-asserted-by":"crossref","unstructured":"Cordido A, Cernadas E, Fern\u00e1ndez-Delgado M, Garc\u00eda-Gonz\u00e1lez MA. CystAnalyser: A new software tool for the automatic detection and quantification of cysts in Polycystic Kidney and Liver Disease, and other cystic disorders. Pertea M, ed. PLoS Comput Biol. 2020;16(10). doi:10.1371\/journal.pcbi.1008337.","DOI":"10.1371\/journal.pcbi.1008337"},{"key":"10.1016\/j.bcp.2025.116858_b0190","doi-asserted-by":"crossref","unstructured":"Cordido A. Nu\u00f1ez-Gonzalez L. Martinez-Moreno J. J.M. Martinez-Moreno O. Lamas-Gonzalez L. Rodriguez-Osorio M.V. Perez-Gomez D. Martin-Sanchez P. Outeda M. Chiaravalli T. Watnick A. Boletta C. Diaz A. Carracedo A.B. Sanz A. Ortiz M.A. Garcia-Gonzalez Tweak signaling pathway blockade slows cyst growth and disease progression in autosomal dominant polycystic kidney disease J Am Soc Nephrol. 32 8 2021 1913 1932 10.1681\/ASN.2020071094.","DOI":"10.1681\/ASN.2020071094"},{"issue":"1","key":"10.1016\/j.bcp.2025.116858_b0195","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/nar\/gkg034","article-title":"STRING: A database of predicted functional associations between proteins","volume":"31","author":"von Mering","year":"2003","journal-title":"Nucleic Acids Res.."},{"issue":"1","key":"10.1016\/j.bcp.2025.116858_b0200","doi-asserted-by":"crossref","DOI":"10.1186\/s12859-017-1559-2","article-title":"Reactome pathway analysis: A high-performance in-memory approach","volume":"18","author":"Fabregat","year":"2017","journal-title":"BMC Bioinf.."},{"issue":"10","key":"10.1016\/j.bcp.2025.116858_b0205","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/oxfordjournals.annonc.a059091","article-title":"Matrix metalloproteinase inhibition: A review of anti-tumour activity","volume":"6","author":"Brown","year":"1995","journal-title":"Ann. Oncol.."},{"key":"10.1016\/j.bcp.2025.116858_b0210","doi-asserted-by":"crossref","unstructured":"Cancer Chemotherapy and Pharmacology, Supplement Steward WP Marimastat (BB2516): current status of development Cancer Chemother. Pharmacol. 43 7 1999 S56 S60 10.1007\/s002800051099.","DOI":"10.1007\/s002800051099"},{"key":"10.1016\/j.bcp.2025.116858_b0215","unstructured":"Song CJ Zimmerman K.A. Henke S.J. Yoder B.K. Molecular biology 10.1007\/978-3-319-51436-9."},{"issue":"12","key":"10.1016\/j.bcp.2025.116858_b0220","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/s41588-021-00963-3","article-title":"Reversing polycystic kidney disease","volume":"53","author":"Boletta","year":"2021","journal-title":"Nat. Genet.."},{"issue":"4","key":"10.1016\/j.bcp.2025.116858_b0225","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/ki.1991.87","article-title":"Cytokines in fluids from polycystic kidneys","volume":"39","author":"Gardner","year":"1991","journal-title":"Kidney Int.."},{"issue":"3","key":"10.1016\/j.bcp.2025.116858_b0230","first-page":"619","article-title":"Cytokine profile in autosomal dominant polycystic kidney disease","volume":"41","author":"Merta","year":"1997","journal-title":"Biochem Mol Biol Int."},{"issue":"25","key":"10.1016\/j.bcp.2025.116858_b0235","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N. Engl. J. Med.."},{"issue":"20","key":"10.1016\/j.bcp.2025.116858_b0240","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease","volume":"377","author":"Torres","year":"2017","journal-title":"N. Engl. J. Med.."},{"issue":"11","key":"10.1016\/j.bcp.2025.116858_b0245","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/labinvest.2016.93","article-title":"Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease","volume":"96","author":"Mancinelli","year":"2016","journal-title":"Lab. Invest.."},{"issue":"2","key":"10.1016\/j.bcp.2025.116858_b0250","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/jcp.1041500220","article-title":"Abnormal extracellular matrix and excessive growth of human adult polycystic kidney disease epithelia","volume":"150","author":"Wilson","year":"1992","journal-title":"J. Cell. Physiol.."},{"issue":"9","key":"10.1016\/j.bcp.2025.116858_b0255","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.ki.5000309","article-title":"Transcriptome analysis of a rat PKD model: Importance of genes involved in extracellular matrix metabolism","volume":"69","author":"Riera","year":"2006","journal-title":"Kidney Int.."},{"issue":"109","key":"10.1016\/j.bcp.2025.116858_b0260","first-page":"1","article-title":"Increasing extracellular matrix collagen level and MMP activity induces cyst development in polycystic kidney disease","volume":"13","author":"Liu","year":"2012","journal-title":"BMC Nephrol."},{"issue":"8","key":"10.1016\/j.bcp.2025.116858_b0265","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/labinvest.2012.68","article-title":"Involvement of matrix metalloproteinase-2 in the development of renal interstitial fibrosis in mouse obstructive nephropathy","volume":"92","author":"Du","year":"2012","journal-title":"Lab. Invest.."},{"issue":"5","key":"10.1016\/j.bcp.2025.116858_b0270","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/phy2.90","article-title":"Overexpression of MMP-7 increases collagen 1A2 in the aging kidney","volume":"1","author":"\u015alusarz","year":"2013","journal-title":"Physiol Rep."},{"issue":"1","key":"10.1016\/j.bcp.2025.116858_b0275","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/ki.2013.225","article-title":"TIMP2 and TIMP3 have divergent roles in early renal tubulointerstitial injury","volume":"85","author":"Wang","year":"2014","journal-title":"Kidney Int.."},{"issue":"6","key":"10.1016\/j.bcp.2025.116858_b0280","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1681\/ASN.2008050492","article-title":"Loss of TIMP3 Enhances Interstitial Nephritis and Fibrosis","volume":"20","author":"Kassiri","year":"2009","journal-title":"J Am Soc Nephrol."},{"issue":"9","key":"10.1016\/j.bcp.2025.116858_b0285","doi-asserted-by":"crossref","first-page":"962","DOI":"10.34067\/KID.0001022019","article-title":"Loss of Cilia Does Not Slow Liver Disease Progression in Mouse Models of Autosomal Recessive Polycystic Kidney Disease","volume":"1","author":"Gallagher","year":"2020","journal-title":"Kidney360."},{"issue":"11","key":"10.1016\/j.bcp.2025.116858_b0290","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1681\/ASN.2019020150","article-title":"Synergistic genetic interactions between pkhd1 and pkd1 result in an arpkd-like phenotype in murine models","volume":"30","author":"Olson","year":"2019","journal-title":"J Am Soc Nephrol."},{"issue":"12","key":"10.1016\/j.bcp.2025.116858_b0295","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1681\/ASN.2019030321","article-title":"Proximal tubule-derived amphiregulin amplifies and integrates profibrotic EGF receptor signals in kidney fibrosis","volume":"30","author":"Kefaloyianni","year":"2019","journal-title":"J Am Soc Nephrol."},{"issue":"13","key":"10.1016\/j.bcp.2025.116858_b0300","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87023","article-title":"ADAM17 substrate release in proximal tubule drives kidney fibrosis","volume":"1","author":"Kefaloyianni","year":"2016","journal-title":"JCI Insight."},{"issue":"1","key":"10.1016\/j.bcp.2025.116858_b0305","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-43226-x","article-title":"Epidermal growth factor receptor activation is essential for kidney fibrosis development","volume":"14","author":"Cao","year":"2023","journal-title":"Nat Commun."},{"issue":"1","key":"10.1016\/j.bcp.2025.116858_b0310","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1681\/ASN.2013121312","article-title":"Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model","volume":"26","author":"Hopp","year":"2015","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"10.1016\/j.bcp.2025.116858_b0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002777","article-title":"Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial","volume":"16","author":"Perico","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.bcp.2025.116858_b0320","doi-asserted-by":"crossref","unstructured":"Podrini C. Clerici S. Tronci L. Stefanoni D. Distefano G. Cassina L. Steidl ME Canu T. Chiaravalli M. Spies D. Bell TA Costa AS Esposito A. D'Alessandro A. Frezza C. Bachi A. Boletta A. Inhibition of asparagine synthetase effectively retards polycystic kidney disease progression EMBO Mol. Med. 16 6 2024 1379 1403 10.1101\/2023.10.10.561720.","DOI":"10.1038\/s44321-024-00071-9"},{"issue":"1","key":"10.1016\/j.bcp.2025.116858_b0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3466.2007.00001.x","article-title":"Tolvaptan, an Orally Active Vasopressin V2-Receptor Antagonist\u2014Pharmacology and Clinical Trials","volume":"25","author":"Miyazaki","year":"2007","journal-title":"CardioVasc Drug Rev."},{"issue":"23","key":"10.1016\/j.bcp.2025.116858_b0330","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1200\/JCO.2004.08.054","article-title":"Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group Trial E2196","volume":"22","author":"Sparano","year":"2004","journal-title":"J. Clin. Oncol.."},{"issue":"22","key":"10.1016\/j.bcp.2025.116858_b0335","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1200\/JCO.2002.02.108","volume":"20","author":"Shepherd","year":"2002","journal-title":"J. Clin. Oncol.."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225001200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225001200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:24:11Z","timestamp":1762097051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225001200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":67,"alternative-id":["S0006295225001200"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116858","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic opportunities in polycystic kidney and liver disease through extracellular matrix dynamics","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116858"}}